MyHep All™ is a licensed generic of Epclusa® produced in an FDA approved manufacturing facility in India. It’s a direct-acting antiviral used to treat chronic Hepatitis C (HCV) across all genotypes in patients with or without liver cirrhosis. For most patients, 12 weeks of treatment is needed to reach cure.
- Epclusa® overall established cure rate across all 6 strains of Hepatitis C is roughly 96%
- For treatment experienced genotype 3 patients or for patients with advanced Liver cirrhosis (decompensated), treatment duration is 24 weeks instead of 12 weeks
- Epclusa®’s side effects profile is quite mild especially with enough water intake
- Consult a doctor before concurrent administration of other drugs and supplements to avoid drug interactions
- Epclusa® is approved by the FDA and EMA for use in adults and children aged six years and older or weighing at least 37 pounds (17 kilograms)
Bottle Size : 28 Tablets (4 weeks supply)
Active Ingredients : Sofosbuvir 400 MG / Velpatasvir 100 MG
Produced by Mylan Pharmaceuticals®
Product of India
Reviews
There are no reviews yet.